phospho-FANCA (Ser1149)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 13139R
英文名称phospho-FANCA (Ser1149)
中文名称磷酸化范可尼贫血组蛋白础抗体
别 名FANCA (phospho S1149); p-FANCA (phospho S1149); FA 1; FA; FA H; FA1; FAA; FACA; FAH; Fanca; FANCA_HUMAN; FANCH; Fanconi anemia complementation group A; Fanconi anemia complementation group H; Fanconi anemia group A protein; Fanconi anemia type 1; MGC75158; Protein FACA.
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 细胞生物 发育生物学 染色质和核信号 细胞周期蛋白
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
phospho-FANCA (Ser1149)抗体交叉反应 Human,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量160kDa
细胞定位细胞核 细胞浆
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human FANCA around the phosphorylation site of Ser1149:1101-1300/1455
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-FANCA (Ser1149)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
Fanconi anemia (FA) is an autosomal recessive disorder characterized by bone marrow failure, birth defects and chromosomal instability. At the cellular level, FA is characterized by spontaneous chromosomal breakage and a unique hypersensitivity to DNA cross-linking agents. At least eight complementation groups (A-G) have been identified and six FA genes (for subtypes A, C, D2, E, F and G) have been cloned. The FA proteins lack sequence homologies or motifs that could point to a molecular function. The cellular accumulation of FA proteins, including FANCA and FANCG, is subject to regulation by TNF alpha signaling. Phosphorylation of FANC (Fanconi anemia complementation group) proteins is thought to be important for the function of the FA pathway. FANCA, also known as FACA and FANCH, associates with the Brm-related gene 1 (BRG1) product, a subunit of the SWI/SNF complex which remodels chromatin structure through a DNA-dependent ATPase activity. FANCA is mainly expressed in lymphoid tissues, testis and ovary. The amino-terminal region of the FANCA protein is required for FANCG binding, FANCC binding, nuclear localization and functional activity of the complex. The human FANCA gene maps to chromosome 16q24.3 and encodes a 1,455 amino acid protein.
Function:
DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability.
Subunit:
Belongs to the multisubunit FA complex composed of FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL/PHF9 and FANCM. The complex is not found in FA patients. In complex with FANCF, FANCG and FANCL, but not with FANCC, nor FANCE, interacts with HES1; this interaction may be essential for the stability and nuclear localization of FA core complex proteins. The complex with FANCC and FANCG may also include EIF2AK2 and HSP70. Interacts with FAAP20/C1orf86; interaction is direct.
Subcellular Location:
Nucleus. Cytoplasm. The major form is nuclear. The minor form is cytoplasmic.
Post-translational modifications:
Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylation is required for the formation of the nuclear complex. Not phosphorylated in cells derived from groups A, B, C, E, F, G, and H.
DISEASE:
Defects in FANCA are a cause of Fanconi anemia (FA) [MIM:227650]. FA is a genetically heterogeneous, autosomal recessive disorder characterized by progressive pancytopenia, a diverse assortment of congenital malformations, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage), and defective DNA repair.
SWISS:
O15360
Gene ID:
2175
phospho-FANCA (Ser1149)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-FANCA (Ser1149)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 合格 phospho-ILK-1(Thr173) 磷酸化整合素连接激酶1抗体
合格 合格 phospho-IRS1 (Thr176) 磷酸化胰岛素受体底物1抗体
合格 phospho-IGF1R (Tyr980) 磷酸化胰岛素样生长因子1受体抗体
合格 phospho-IGF1R (Tyr1280) 磷酸化胰岛素样生长因子1受体抗体
合格 phospho-IGF1R (Tyr1165 + Tyr1166) 磷酸化胰岛素样生长因子1受体抗体
合格 phospho-ICAM1 (Tyr512) 磷酸化细胞间粘附分子1抗体
合格 合格 phospho-c-Jun (Thr91) 磷酸化原癌基因c-Jun抗体
合格 phospho-Smad3 (Ser213) 磷酸化细胞信号转导分子SMAD3抗体
合格 phospho-c-Jun(Thr239) 磷酸化原癌基因c-Jun抗体
合格 phospho-c-Jun (Thr249) 磷酸化原癌基因c-Jun抗体
合格 合格 phospho-c-Jun(Tyr170) 磷酸化原癌基因c-Jun抗体
合格 Phospho-MDM2(Thr218) 磷酸化双微体2癌基因抗体
合格 phospho-Tau (Ser416) 磷酸化微管相关蛋白抗体
合格 phospho-MBP(Thr232) 磷酸化髓鞘碱性蛋白抗体
合格 phospho-MBP(Tyr203) 磷酸化髓鞘碱性蛋白抗体
合格 合格 合格 phospho-P38 MAPK (Thr180) 磷酸化p38MAPK抗体
合格 phospho-p38 MAPK (Tyr323) 磷酸化p38MAPK抗体
合格 phospho-MEF2C(Ser387) 磷酸化肌细胞增强因子2C抗体
合格 phospho-MEF2C(Thr300) 磷酸化肌细胞增强因子2C抗体
合格 phospho-ERK5 (Ser496) 磷酸化细胞外信号调节激酶5抗体
合格 Phospho-MEF2A(Thr319) 磷酸化肌细胞增强因子2抗体
合格 phospho-ERK5 ( Ser731+Thr733) 磷酸化细胞外信号调节激酶5抗体
合格 合格 phospho-Ron(Tyr1238) 磷酸化原癌基因c-Met相关酪氨酸激酶抗体
合格 phospho-MAP4K4(Ser801) 磷酸化丝裂原活化蛋白激酶MAP4K4抗体
合格 phospho-MAP4K1(Ser171) 磷酸化造血祖细胞激酶抗体
合格 phospho-MAP3K7IP1 (Thr431) 磷酸化转化生长因子β活化激酶结合蛋白1抗体
合格 phospho-MEF2D(Ser180) 磷酸化肌细胞特异性增强因子2D抗体